
Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
Oncology Today with Dr Neil Love
00:00
Incidence and Onset for Inavolisib and Capivasertib
Giuseppe Curigliano states hyperglycemia incidence (~60–65%) and median onset times for inavolisib and capivasertib.
Play episode from 56:01
Transcript


